Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences names new head of oncology therapeutics

Gilead Sciences names new head of oncology therapeutics

18th October 2017

Gilead Sciences has announced the appointment of Dr Alessandro Riva as the company's new executive vice-president for oncology therapeutics.

Dr Riva has been with the firm since January 2017 in the role of senior vice-president for haematology and oncology, playing a key part in expanding Gilead's oncology programme with the recent acquisition of Kite Pharma, as well as guiding the strategy and development of its broader oncology pipeline.

Before joining Gilead, he served as head of global oncology development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds spanning a variety of tumour types.

In his new role at Gilead, Dr Riva will assume overall responsibility for the company's haematology and oncology programmes, including cell therapy research and development, as well as becoming a member of Gilead's senior leadership team.

Dr John McHutchison, executive vice-president for clinical research at Gilead Sciences, said: "Alessandro's vision and insight have helped Gilead broaden and deepen our oncology pipeline through the acquisition of Kite Pharma, and his exceptional leadership has guided the company’s broader haematology/oncology strategy."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.